Texas Sues Pharma Giant Sanofi Over Alleged Provider Bribery Scheme

AUSTIN, Texas — Texas Attorney General Ken Paxton escalated his legal campaign against the pharmaceutical industry on Thursday, filing a major lawsuit against Sanofi. The state accuses the French drugmaker of orchestrating a bribery scheme that used “free” support services to improperly influence doctors into prescribing its medications over competing treatments.

The lawsuit, filed on February 19, 2026, in state district court, alleges that Sanofi violated the Texas Health Care Program Fraud Prevention Act. By offering specialized services to healthcare providers at no cost—services the state characterizes as illegal kickbacks—Sanofi allegedly induced medical professionals to favor its products, potentially inflating costs for taxpayer-funded programs like Medicaid.

Attorney General Paxton is seeking civil penalties exceeding $1 million and a permanent injunction to halt the alleged practices.

The Allegations: Support or Subversion?

The core of the state’s complaint rests on the fine line between patient assistance and illegal inducements. Texas alleges that Sanofi structured its “patient support programs” not out of altruism, but as a strategic tool to sway clinical judgment.

According to the filing, these programs provided services such as administrative help and reimbursement support that saved healthcare providers time and money. The state argues these benefits functioned as bribes, creating a “quid pro quo” where Sanofi’s drugs were prioritized for patients regardless of whether they were the most cost-effective or clinically appropriate option.

“Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme,” Paxton stated in a press release following the filing. “We are going to make Sanofi pay a heavy cost for their lack of regard for Texans and the state’s clear laws.”

A Pattern of Legal Friction

This is not Sanofi’s first brush with such allegations. In 2018, the company paid $25.2 million to settle U.S. Securities and Exchange Commission (SEC) charges related to bribery schemes involving foreign officials in Kazakhstan and the Middle East. Furthermore, Texas is currently pursuing Sanofi in a separate 2025 lawsuit involving the blood thinner Plavix, alleging the company failed to disclose that the drug was ineffective for certain genetic profiles common in Black and Asian populations.

Sanofi Vows “Zealous” Defense

Sanofi has moved quickly to distance itself from the allegations of wrongdoing. In a public statement, the company maintained that its programs are designed to assist patients in navigating complex treatments and adhering to their medication schedules—a key component of managing chronic illness.

“Our programs are structured to comply with applicable federal and state laws and are intended to support patients, not to influence prescribing decisions,” a Sanofi spokesperson said. “The company is zealously defending this litigation.”

Industry groups often argue that such programs are vital. For instance, a 2023 study published in Health Affairs suggested that patient-support initiatives could reduce emergency room visits for diabetes patients by as much as 15% by improving medication adherence.

Expert Perspective: The “Gray Area” of Pharma Marketing

Legal and medical experts note that the distinction between a “value-added service” and a “bribe” is often a legal gray area.

“Pharmaceutical support services, like patient education or adherence programs, are common but must avoid any direct incentive for prescriptions,” says Dr. Aaron Kesselheim, a professor of medicine and law at Brigham and Women’s Hospital and Harvard Medical School. Dr. Kesselheim, who is not involved in the Texas litigation, explains that these cases are difficult to prove because the services often appear legitimate on the surface.

Dr. Reshma Patel, a primary care physician at Johns Hopkins Medicine, emphasizes the importance of trust. “Patients deserve transparency. Any program that blurs the line between education and promotion erodes confidence in the entire healthcare system,” she noted.

Public Health and Economic Impact

The lawsuit comes at a time of heightened scrutiny over U.S. prescription drug spending, which reached $646 billion in 2024. In Texas, the Medicaid program serves over 4 million low-income residents. In fiscal year 2024 alone, Texas Medicaid spent approximately $8.5 billion on prescription drugs.

If Sanofi’s actions resulted in “tainted” prescriptions, the financial burden falls directly on taxpayers. Beyond the cost, there are clinical concerns. When financial incentives influence a doctor’s pen, patients may be steered away from cheaper generics or more suitable alternatives.

Broader Industry Crackdown

This lawsuit is part of a broader trend of “Anti-Pharma” litigation in Texas:

• August 2025: Texas sued Eli Lilly over alleged bribery to boost GLP-1 weight-loss drugs like Mounjaro.

• October 2024: Paxton sued Sanofi, Eli Lilly, and Novo Nordisk over insulin pricing “conspiracies.”

• November 2025: A suit was filed against Sanofi and Bristol-Myers Squibb regarding Plavix marketing.

What This Means for Patients

For the average consumer, the legal battle highlights the importance of shared decision-making with healthcare providers. Patients are encouraged to ask their doctors:

1. Is there a generic alternative to this brand-name drug?

2. Are there other effective treatments that might be more affordable?

3. Why is this specific medication being recommended over others?

While the legal process may take years to resolve, the discovery phase of the lawsuit is expected to reveal internal emails and data that could provide a clearer look at how drug companies and doctor’s offices interact behind closed doors.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• Reuters. (2026, Feb 19). Texas sues Sanofi for allegedly ‘bribing’ providers to boost drug prescriptions.